| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | aspartic-type endopeptidase activity | 1.48e-18 | 37 | 17 | 8 | GO:0004190 | |
| GeneOntologyMolecularFunction | aspartic-type peptidase activity | 1.88e-18 | 38 | 17 | 8 | GO:0070001 | |
| GeneOntologyMolecularFunction | RNA-DNA hybrid ribonuclease activity | 1.08e-13 | 11 | 17 | 5 | GO:0004523 | |
| GeneOntologyMolecularFunction | RNA-directed DNA polymerase activity | 4.66e-13 | 14 | 17 | 5 | GO:0003964 | |
| GeneOntologyMolecularFunction | RNA stem-loop binding | 4.72e-12 | 21 | 17 | 5 | GO:0035613 | |
| GeneOntologyMolecularFunction | endopeptidase activity | ERVK-18 ERVK-8 ERVK-6 OMA1 ERVK-19 ERVK-7 ERVK-25 ERVK-9 ERVK-10 | 1.91e-11 | 430 | 17 | 9 | GO:0004175 |
| GeneOntologyMolecularFunction | RNA endonuclease activity, producing 5'-phosphomonoesters | 1.00e-10 | 37 | 17 | 5 | GO:0016891 | |
| GeneOntologyMolecularFunction | DNA polymerase activity | 1.16e-10 | 38 | 17 | 5 | GO:0034061 | |
| GeneOntologyMolecularFunction | endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters | 3.14e-10 | 46 | 17 | 5 | GO:0016893 | |
| GeneOntologyMolecularFunction | peptidase activity | ERVK-18 ERVK-8 ERVK-6 OMA1 ERVK-19 ERVK-7 ERVK-25 ERVK-9 ERVK-10 | 7.89e-10 | 654 | 17 | 9 | GO:0008233 |
| GeneOntologyMolecularFunction | nucleotidyltransferase activity | 2.03e-09 | 152 | 17 | 6 | GO:0016779 | |
| GeneOntologyMolecularFunction | RNA endonuclease activity | 5.08e-09 | 79 | 17 | 5 | GO:0004521 | |
| GeneOntologyMolecularFunction | structural molecule activity | ERVK-18 ERVK-8 COL2A1 ERVK-6 ERVK-19 ERVK-7 ERVK-25 ERVK-9 ERVK-10 | 1.19e-08 | 891 | 17 | 9 | GO:0005198 |
| GeneOntologyMolecularFunction | catalytic activity, acting on DNA | 5.28e-08 | 262 | 17 | 6 | GO:0140097 | |
| GeneOntologyMolecularFunction | RNA nuclease activity | 7.89e-08 | 136 | 17 | 5 | GO:0004540 | |
| GeneOntologyMolecularFunction | endonuclease activity | 7.89e-08 | 136 | 17 | 5 | GO:0004519 | |
| GeneOntologyMolecularFunction | zinc ion binding | 2.59e-07 | 891 | 17 | 8 | GO:0008270 | |
| GeneOntologyMolecularFunction | nuclease activity | 1.10e-06 | 231 | 17 | 5 | GO:0004518 | |
| GeneOntologyMolecularFunction | transition metal ion binding | 2.31e-06 | 1189 | 17 | 8 | GO:0046914 | |
| GeneOntologyMolecularFunction | transferase activity, transferring phosphorus-containing groups | 6.34e-06 | 938 | 17 | 7 | GO:0016772 | |
| GeneOntologyMolecularFunction | catalytic activity, acting on a nucleic acid | 1.01e-05 | 645 | 17 | 6 | GO:0140640 | |
| GeneOntologyMolecularFunction | catalytic activity, acting on RNA | 1.95e-05 | 417 | 17 | 5 | GO:0140098 | |
| GeneOntologyMolecularFunction | hydrolase activity, acting on ester bonds | 4.39e-04 | 807 | 17 | 5 | GO:0016788 | |
| GeneOntologyBiologicalProcess | DNA integration | 2.55e-13 | 13 | 17 | 5 | GO:0015074 | |
| GeneOntologyBiologicalProcess | DNA synthesis involved in DNA repair | 3.34e-10 | 48 | 17 | 5 | GO:0000731 | |
| GeneOntologyBiologicalProcess | RNA-templated DNA biosynthetic process | 5.56e-09 | 83 | 17 | 5 | GO:0006278 | |
| GeneOntologyBiologicalProcess | cell-cell fusion | 6.28e-09 | 85 | 17 | 5 | GO:0140253 | |
| GeneOntologyBiologicalProcess | syncytium formation by plasma membrane fusion | 6.28e-09 | 85 | 17 | 5 | GO:0000768 | |
| GeneOntologyBiologicalProcess | syncytium formation | 7.93e-09 | 89 | 17 | 5 | GO:0006949 | |
| GeneOntologyBiologicalProcess | DNA-templated DNA replication | 2.57e-07 | 178 | 17 | 5 | GO:0006261 | |
| GeneOntologyBiologicalProcess | DNA recombination | 3.25e-07 | 368 | 17 | 6 | GO:0006310 | |
| GeneOntologyBiologicalProcess | DNA biosynthetic process | 7.03e-07 | 218 | 17 | 5 | GO:0071897 | |
| GeneOntologyBiologicalProcess | viral process | 1.26e-06 | 464 | 17 | 6 | GO:0016032 | |
| GeneOntologyBiologicalProcess | DNA replication | 4.09e-06 | 312 | 17 | 5 | GO:0006260 | |
| GeneOntologyBiologicalProcess | DNA repair | 8.65e-06 | 648 | 17 | 6 | GO:0006281 | |
| GeneOntologyBiologicalProcess | DNA damage response | 7.91e-05 | 959 | 17 | 6 | GO:0006974 | |
| GeneOntologyBiologicalProcess | DNA metabolic process | 1.53e-04 | 1081 | 17 | 6 | GO:0006259 | |
| GeneOntologyBiologicalProcess | anatomical structure formation involved in morphogenesis | 8.48e-04 | 1483 | 17 | 6 | GO:0048646 | |
| HumanPheno | Fused cervical vertebrae | 2.94e-06 | 35 | 5 | 3 | HP:0002949 | |
| HumanPheno | Vertebral fusion | 2.88e-05 | 74 | 5 | 3 | HP:0002948 | |
| HumanPheno | Flat acetabular roof | 2.88e-04 | 28 | 5 | 2 | HP:0003180 | |
| HumanPheno | Vertebral segmentation defect | 3.01e-04 | 162 | 5 | 3 | HP:0003422 | |
| HumanPheno | Bifid uvula | 3.30e-04 | 167 | 5 | 3 | HP:0000193 | |
| HumanPheno | Glossoptosis | 3.78e-04 | 32 | 5 | 2 | HP:0000162 | |
| HumanPheno | Gastroparesis | 4.27e-04 | 34 | 5 | 2 | HP:0002578 | |
| HumanPheno | Abnormal uvula morphology | 5.38e-04 | 197 | 5 | 3 | HP:0000172 | |
| HumanPheno | Synostosis of joints | 6.68e-04 | 212 | 5 | 3 | HP:0100240 | |
| HumanPheno | Short femoral neck | 7.17e-04 | 44 | 5 | 2 | HP:0100864 | |
| HumanPheno | Abnormally large globe | 7.50e-04 | 45 | 5 | 2 | HP:0001090 | |
| HumanPheno | Aplasia/Hypoplasia involving the femoral head and neck | 8.19e-04 | 47 | 5 | 2 | HP:0009108 | |
| HumanPheno | Tracheomalacia | 8.90e-04 | 49 | 5 | 2 | HP:0002779 | |
| HumanPheno | Cleft soft palate | 9.39e-04 | 238 | 5 | 3 | HP:0000185 | |
| HumanPheno | Cleft secondary palate | 9.63e-04 | 240 | 5 | 3 | HP:0410004 | |
| HumanPheno | Coarse facial features | 9.86e-04 | 242 | 5 | 3 | HP:0000280 | |
| HumanPheno | Abnormal male reproductive system physiology | 1.14e-03 | 1314 | 5 | 5 | HP:0012874 | |
| HumanPheno | Spinal rigidity | 1.29e-03 | 59 | 5 | 2 | HP:0003306 | |
| HumanPheno | Wormian bones | 1.38e-03 | 61 | 5 | 2 | HP:0002645 | |
| HumanPheno | Abnormal fibula morphology | 1.42e-03 | 62 | 5 | 2 | HP:0002991 | |
| HumanPheno | Abnormality of refraction | 1.66e-03 | 709 | 5 | 4 | HP:0000539 | |
| HumanPheno | Abnormal soft palate morphology | 1.66e-03 | 289 | 5 | 3 | HP:0100736 | |
| HumanPheno | Abnormal morphology of the radius | 1.66e-03 | 67 | 5 | 2 | HP:0045009 | |
| HumanPheno | Cupped ear | 1.76e-03 | 69 | 5 | 2 | HP:0000378 | |
| HumanPheno | Submucous cleft hard palate | 1.92e-03 | 72 | 5 | 2 | HP:0000176 | |
| HumanPheno | Submucous cleft of soft and hard palate | 1.92e-03 | 72 | 5 | 2 | HP:0410031 | |
| HumanPheno | Submucous cleft lip/palate | 2.02e-03 | 74 | 5 | 2 | HP:0000208 | |
| HumanPheno | Gait imbalance | 2.02e-03 | 74 | 5 | 2 | HP:0002141 | |
| HumanPheno | Aplasia/hypoplasia of the femur | 2.02e-03 | 74 | 5 | 2 | HP:0005613 | |
| HumanPheno | Abnormality of balance | 2.02e-03 | 74 | 5 | 2 | HP:0100683 | |
| HumanPheno | Forearm undergrowth | 2.08e-03 | 75 | 5 | 2 | HP:0009821 | |
| HumanPheno | Aplasia/Hypoplasia involving the pelvis | 2.13e-03 | 76 | 5 | 2 | HP:0009103 | |
| HumanPheno | Cleft hard palate | 2.19e-03 | 77 | 5 | 2 | HP:0410005 | |
| HumanPheno | Closed neural tube defect | 2.30e-03 | 79 | 5 | 2 | HP:0034238 | |
| HumanPheno | Submucous cleft palate | 2.54e-03 | 83 | 5 | 2 | HP:5201016 | |
| HumanPheno | Upper limb undergrowth | 2.73e-03 | 86 | 5 | 2 | HP:0009824 | |
| HumanPheno | Abnormal acetabulum morphology | 3.11e-03 | 92 | 5 | 2 | HP:0003170 | |
| HumanPheno | Abnormal auditory canal morphology | 3.53e-03 | 98 | 5 | 2 | HP:0000372 | |
| HumanPheno | Abnormal lower limb bone morphology | 3.59e-03 | 866 | 5 | 4 | HP:0040069 | |
| MousePheno | increased circulating lipase level | 1.15e-04 | 29 | 8 | 2 | MP:0011886 | |
| MousePheno | abnormal circulating lipase level | 1.24e-04 | 30 | 8 | 2 | MP:0011885 | |
| MousePheno | granulomatous inflammation | 1.79e-04 | 36 | 8 | 2 | MP:0002500 | |
| Pubmed | A revised nomenclature for transcribed human endogenous retroviral loci. | ERVK-18 ERVK-8 ERVK-11 ERVK-6 ERVK-19 ERVK-7 ERVK-25 ERVK-9 ERVK-10 | 1.24e-19 | 94 | 17 | 9 | 21542922 |
| Pubmed | 1.25e-13 | 18 | 17 | 5 | 18664271 | ||
| Pubmed | Quantitation of HERV-K env gene expression and splicing in human breast cancer. | 1.95e-13 | 5 | 17 | 4 | 12629516 | |
| Pubmed | 1.93e-11 | 12 | 17 | 4 | 14557543 | ||
| Pubmed | 9.70e-11 | 3 | 17 | 3 | 10516026 | ||
| Pubmed | 9.70e-11 | 3 | 17 | 3 | 9971820 | ||
| Pubmed | 3.88e-10 | 4 | 17 | 3 | 7983737 | ||
| Pubmed | Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. | 3.88e-10 | 4 | 17 | 3 | 10469592 | |
| Pubmed | 1.94e-09 | 6 | 17 | 3 | 15063128 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 9060628 | ||
| Pubmed | Evolutionary relationships within a subgroup of HERV-K-related human endogenous retroviruses. | 2.25e-07 | 2 | 17 | 2 | 9460924 | |
| Pubmed | Interferon-alpha-induced endogenous superantigen. a model linking environment and autoimmunity. | 2.25e-07 | 2 | 17 | 2 | 11672541 | |
| Pubmed | Transcriptionally active HERV-K genes: identification, isolation, and chromosomal mapping. | 2.25e-06 | 5 | 17 | 2 | 11401426 | |
| Pubmed | 1.01e-05 | 10 | 17 | 2 | 12970426 | ||
| Pubmed | 2.01e-04 | 43 | 17 | 2 | 26030138 | ||
| Coexpression | PTEN_DN.V2_UP | 7.66e-04 | 139 | 8 | 2 | M2759 | |
| Coexpression | OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_UP | 8.44e-04 | 146 | 8 | 2 | M41190 | |
| Coexpression | UEDA_PERIFERAL_CLOCK | 1.15e-03 | 171 | 8 | 2 | M12498 | |
| Coexpression | GSE14415_ACT_TCONV_VS_ACT_NATURAL_TREG_UP | 1.17e-03 | 172 | 8 | 2 | M2945 | |
| Coexpression | UEDA_PERIFERAL_CLOCK | 1.24e-03 | 177 | 8 | 2 | MM1145 | |
| Coexpression | GSE11057_EFF_MEM_VS_CENT_MEM_CD4_TCELL_DN | 1.41e-03 | 189 | 8 | 2 | M3112 | |
| Coexpression | RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN | 1.45e-03 | 807 | 8 | 3 | M16651 | |
| Coexpression | GSE29618_BCELL_VS_MDC_UP | 1.48e-03 | 194 | 8 | 2 | M4943 | |
| Coexpression | GSE2770_TGFB_AND_IL4_VS_IL4_TREATED_ACT_CD4_TCELL_6H_UP | 1.48e-03 | 194 | 8 | 2 | M6103 | |
| Coexpression | GSE20727_CTRL_VS_H2O2_TREATED_DC_DN | 1.51e-03 | 196 | 8 | 2 | M9243 | |
| Coexpression | GSE37416_0H_VS_3H_F_TULARENSIS_LVS_NEUTROPHIL_DN | 1.53e-03 | 197 | 8 | 2 | M5342 | |
| Coexpression | GSE20727_CTRL_VS_H2O2_TREATED_DC_UP | 1.54e-03 | 198 | 8 | 2 | M9245 | |
| Coexpression | GSE22886_NAIVE_VS_IGG_IGA_MEMORY_BCELL_UP | 1.54e-03 | 198 | 8 | 2 | M4432 | |
| Coexpression | GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_BCELL_UP | 1.54e-03 | 198 | 8 | 2 | M4982 | |
| Coexpression | GSE40225_WT_VS_RIP_B7X_DIABETIC_MOUSE_PANCREATIC_CD8_TCELL_UP | 1.56e-03 | 199 | 8 | 2 | M9238 | |
| Coexpression | GSE8384_CTRL_VS_B_ABORTUS_4H_MAC_CELL_LINE_UP | 1.56e-03 | 199 | 8 | 2 | M5753 | |
| Coexpression | GSE13306_LAMINA_PROPRIA_VS_SPLEEN_TREG_UP | 1.56e-03 | 199 | 8 | 2 | M3217 | |
| Coexpression | GSE15330_WT_VS_IKAROS_KO_LYMPHOID_MULTIPOTENT_PROGENITOR_DN | 1.57e-03 | 200 | 8 | 2 | M7058 | |
| Coexpression | GSE36527_CD62L_HIGH_CD69_NEG_VS_CD62L_LOW_CD69_POS_TREG_KLRG1_NEG_DN | 1.57e-03 | 200 | 8 | 2 | M9028 | |
| Coexpression | GSE27859_DC_VS_CD11C_INT_F480_INT_DC_UP | 1.57e-03 | 200 | 8 | 2 | M8596 | |
| Coexpression | GSE27859_CD11C_INT_F480_HI_MACROPHAGE_VS_CD11C_ING_F480_INT_DC_DN | 1.57e-03 | 200 | 8 | 2 | M8598 | |
| Coexpression | GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_24H_DN | 1.57e-03 | 200 | 8 | 2 | M9925 | |
| Coexpression | GSE14308_TH17_VS_NATURAL_TREG_DN | 1.57e-03 | 200 | 8 | 2 | M3390 | |
| Coexpression | GSE14308_INDUCED_VS_NATURAL_TREG_DN | 1.57e-03 | 200 | 8 | 2 | M3399 | |
| Coexpression | GSE369_PRE_VS_POST_IL6_INJECTION_IFNG_WT_LIVER_DN | 1.57e-03 | 200 | 8 | 2 | M5980 | |
| Coexpression | GSE17301_IFNA2_VS_IFNA2_AND_ACD3_ACD28_STIM_CD8_TCELL_UP | 1.57e-03 | 200 | 8 | 2 | M8042 | |
| Coexpression | GSE17721_CPG_VS_GARDIQUIMOD_2H_BMDC_DN | 1.57e-03 | 200 | 8 | 2 | M3882 | |
| Coexpression | GSE22601_DOUBLE_POSITIVE_VS_CD8_SINGLE_POSITIVE_THYMOCYTE_UP | 1.57e-03 | 200 | 8 | 2 | M6253 | |
| Coexpression | GSE44649_NAIVE_VS_ACTIVATED_CD8_TCELL_MIR155_KO_DN | 1.57e-03 | 200 | 8 | 2 | M9777 | |
| Coexpression | GSE20198_IL12_IL18_VS_IFNA_TREATED_ACT_CD4_TCELL_UP | 1.57e-03 | 200 | 8 | 2 | M7370 | |
| Coexpression | GSE5542_IFNA_VS_IFNA_AND_IFNG_TREATED_EPITHELIAL_CELLS_6H_UP | 1.57e-03 | 200 | 8 | 2 | M6537 | |
| Coexpression | GSE17721_0.5H_VS_4H_GARDIQUIMOD_BMDC_UP | 1.57e-03 | 200 | 8 | 2 | M4139 | |
| Coexpression | GSE17721_0.5H_VS_24H_GARDIQUIMOD_BMDC_UP | 1.57e-03 | 200 | 8 | 2 | M4143 | |
| Coexpression | GSE43957_UNTREATED_VS_NACL_TREATED_ANTI_CD3_CD28_STIM_CD4_TCELL_DN | 1.57e-03 | 200 | 8 | 2 | M9625 | |
| Coexpression | GSE20366_EX_VIVO_VS_HOMEOSTATIC_CONVERSION_NAIVE_CD4_TCELL_UP | 1.57e-03 | 200 | 8 | 2 | M4323 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.42e-06 | 195 | 8 | 3 | 3e519cffa6144a62b06124642a14c9ff39b76554 | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 4.77e-06 | 200 | 8 | 3 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | Severe-B_naive-11|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 3.51e-04 | 161 | 8 | 2 | ad3b58e3a8b59a609c8d2d2690d15218d18eabbd | |
| ToppCell | Severe-B_naive-11|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 3.96e-04 | 171 | 8 | 2 | 7c2699f19ca38414447a286f7658f507882d57c2 | |
| ToppCell | wk_20-22-Mesenchymal-Chondrocyte-intermediate_chondrocyte|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 4.53e-04 | 183 | 8 | 2 | 1464b5c4425e8776c4aeb4d2b560481d4bf13931 | |
| ToppCell | droplet-Marrow-nan-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 184 | 8 | 2 | 1154a5ad7b8512272b7476f949ddac350910bfb7 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.63e-04 | 185 | 8 | 2 | 7adfa929930cfa795cbfbd9f1a0b439e08aa765d | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-B_lymphocytic-naive_B_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.83e-04 | 189 | 8 | 2 | e2bb5900d210386b7b74938e7a3636d0c7ba1bcf | |
| ToppCell | PND10|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.89e-04 | 190 | 8 | 2 | d67e2814047c8df2ae4b7bc8be9539f5df6ecef2 | |
| ToppCell | Mild/Remission-B_naive-11|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 4.94e-04 | 191 | 8 | 2 | ebb165096de301ba663703d1662d9413ea317867 | |
| ToppCell | Mild/Remission-B_naive-11|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 4.99e-04 | 192 | 8 | 2 | c6f325cddce43b72f013b21dfffc9987fd68b6a7 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.14e-04 | 195 | 8 | 2 | 7796ea9247f4c63762f0de8490fed08b9717fa23 | |
| ToppCell | CV-Moderate-6|Moderate / Virus stimulation, Condition and Cluster | 5.14e-04 | 195 | 8 | 2 | 2b8a72d7e755b9655c7a496000d10ff06e50862b | |
| ToppCell | CV-Moderate-6|CV / Virus stimulation, Condition and Cluster | 5.20e-04 | 196 | 8 | 2 | 7bced0cc2112697593c478fa291b8ed3941fb811 | |
| ToppCell | Control-Control-Myeloid-immature_Neutrophil|Control / Disease, condition lineage and cell class | 5.41e-04 | 200 | 8 | 2 | 118321ac443feb42aee171baccfc4610f00a8822 | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.41e-04 | 200 | 8 | 2 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| Drug | Pa-5 | 7.00e-05 | 29 | 10 | 2 | CID000191445 | |
| Drug | GSK-3 Inhibitor IX; Up 200; 0.5uM; PC3; HT_HG-U133A | 7.21e-05 | 196 | 10 | 3 | 6559_UP | |
| Drug | vicriviroc | 1.55e-04 | 43 | 10 | 2 | CID003009355 | |
| Drug | torcetrapib | 3.73e-04 | 342 | 10 | 3 | ctd:C483909 | |
| Drug | poly (A | 4.74e-04 | 75 | 10 | 2 | CID000439298 | |
| Drug | AC1L8TZY | 4.86e-04 | 76 | 10 | 2 | CID000408095 | |
| Drug | toluidine blue | 5.66e-04 | 82 | 10 | 2 | CID000007083 | |
| Drug | ddTTP | 6.22e-04 | 86 | 10 | 2 | CID000065051 | |
| Drug | cyclohexen-1-amine | 1.03e-03 | 111 | 10 | 2 | CID000445358 | |
| Drug | Muramyl dipeptide | 1.27e-03 | 123 | 10 | 2 | CID000040846 | |
| Disease | leprosy | 4.28e-04 | 103 | 9 | 2 | EFO_0001054 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| VKKNPGIAAKWWNPP | 231 | Q9Y2D5 | |
| PPPTNKWQLDNWLNK | 466 | Q9UHB7 | |
| PNPANVPKKNWWSSK | 1326 | P02458 | |
| EKPVWVNQWPLPKQK | 31 | P63132 | |
| EKPVWVNQWPLPKQK | 31 | P63135 | |
| EKPVWVNQWPLPKQK | 31 | Q9BXR3 | |
| EKLVWVNQWPLPKQK | 31 | Q9QC07 | |
| SKWEWPNPVLLKQPE | 276 | Q9BWT3 | |
| TKIKKEWWDQIPNPA | 256 | P24394 | |
| VKTWDWKRSPPNVQP | 431 | O75072 | |
| KVQKILIWKWGQPPS | 501 | Q14839 | |
| KWWQALPPNKKEVVK | 171 | Q96E52 | |
| NQWPKNWPKQKAVTG | 816 | P63128 | |
| WKTEKPVWVNQWPLP | 951 | P63128 | |
| PVWVNQWPLPKQKLE | 956 | P63128 | |
| EKPVWVNQWPLPKQK | 31 | P63136 | |
| EKPVWVNQWPLPKQK | 31 | P10266 | |
| EKLVWVNQWPLPKQK | 31 | P63133 | |
| EKPVWVNQWPLPKQK | 31 | Q9UQG0 | |
| GVVWEVKPKQKWKPF | 3116 | Q709C8 | |
| LNQWPKNWPKQKTVT | 36 | P63123 | |
| EKPVWVNQWPLPKQK | 31 | Q9WJR5 | |
| LNQWPKNWPKQKAVI | 36 | P63122 |